Wegovy Pill Sees Strong Early Adoption, Signaling Shift in Obesity Treatment
Event summary
- Novo Nordisk's oral Wegovy pill achieved 70%+ physician prescribing rates in its first month post-FDA approval in December 2025.
- 78% of endocrinologists and 73% of primary care physicians reported prescribing the oral GLP-1 therapy by February 2026.
- Unaided awareness among physicians surged from single digits pre-approval to 60%-78% post-launch.
- Early data suggests the oral formulation may expand the obesity treatment market rather than just cannibalize injectable sales.
- Eli Lilly's competing oral GLP-1 candidate, orforglipron, is expected to enter the market in Q2 2026.
The big picture
The rapid adoption of Novo Nordisk's oral Wegovy pill underscores growing physician and patient preference for non-injectable obesity treatments. This shift comes as the GLP-1 market approaches $100 billion in projected global revenue, with intensifying competition between Novo Nordisk and Eli Lilly shaping the future of weight management therapies. The success of oral formulations could expand the total addressable market by attracting patients previously reluctant to use injectable treatments.
What we're watching
- Competitive Differentiation
- How Novo Nordisk will position its oral formulation against Eli Lilly's upcoming orforglipron in terms of efficacy, tolerability, and administration requirements.
- Market Expansion
- Whether the oral GLP-1 therapies can convert treatment-deferring patients into long-term users, driving net market growth.
- Physician Adoption
- The pace at which remaining non-prescribers will adopt the oral formulation, particularly among specialists and primary care physicians.
Related topics